EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Expression conditions and characterization of a novelly constructed lipoprotein intended as a vaccine to prevent human Haemophilus influenzae infections

Ravinder Kaur, Jill Mangiafesto, Karin Pryharski, Sailee Rasam, Robert Zagursky, Michael Pichichero

Journal of Biological Chemistry · 2023

DOI: 10.1016/j.jbc.2023.105031 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2023. Verfasst von Ravinder Kaur und 5 weiteren Autor:innen. Beteiligte Einrichtung: Center for Infectious Diseases and Immunology, Rochester General Hospital Research Institute, Rochester, New York, USA. Electronic address: Ravinder.…. Hauptthemen laut MEDLINE: Haemophilus Vaccines, Haemophilus Infections. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Institutes of Health, National Institute on Deafness and Other Communication Disorders.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bacterial lipoproteins are structurally divided into two groups, based on their lipid moieties: diacylated (present in Gram-positive bacteria) and triacylated (present in some Gram-positive and most Gram-negative bacteria). Diacylated and triacylated lipid moieties differ by a single amide-linked fatty acid chain. Lipoproteins induce host innate immune responses by the mammalian Toll-like receptor 2 (TLR2). In this study, we added a lipid moiety to recombinant OMP26, a native nonlipidated (NL) membrane protein of Haemophilus influenzae, and characterized it extensively under different expression conditions using flow cytometry, LC/MS, and MALDI-TOF. We also investigated the ability of NL and lipidated (L) OMP26 to induce in vitro stimulation of HEK Blue-hTLR2-TR1 and hTLR-TLR6 cells. Our L-OMP26 was predominantly expressed in diacylated form, so we employed an additional gene copy of apolipoprotein N-acetyltransferase enzyme (Lnt)-rich Escherichia coli strain that further acylates the diacyl lipoproteins to enhance the production of triacylated L-OMP26. The diacyl and triacyl versions of L-OMP26, intended as a vaccine for use in humans, were characterized and evaluated as protein vaccine components in a mouse model. We found that the diacyl and triacyl L-OMP26 protein formulations differed markedly in their immune-stimulatory activity, with diacylated L-OMP26 stimulating higher adaptive immune responses compared with triacylated L-OMP26 and both stimulating higher adaptive immune response compared to NL-OMP26. We also constructed and characterized an L-OMP26φNL-P6 fusion protein, where NL-P6 protein (a commonly studied H. influenzae vaccine candidate) was recombinantly fused to L-OMP26. We observed a similar pattern of lipidation (predominantly diacylated) in the L-OMP26φNL-P6 fusion protein.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Haemophilus VaccinesHaemophilus InfectionsMiceAnimalsHumansBacterial Outer Membrane ProteinsLipoproteinsRecombinant ProteinsHaemophilus influenzaeMammals

Stichwörter der Autor:innen

Haemophilus influenzaeOMP26diacylationlipidated recombinant proteinstriacylation

Substanzen

Bacterial Outer Membrane ProteinsLipoproteinsHaemophilus VaccinesRecombinant Proteins

Autor:innen und Institutionen

  • Center for Infectious Diseases and Immunology, Rochester General Hospital Research Institute, Rochester, New York, USA. Electronic address: Ravinder.kaur@rochesterregional.org.
  • Center for Infectious Diseases and Immunology, Rochester General Hospital Research Institute, Rochester, New York, USA.
  • Department of Biochemistry, State University of New York at Buffalo, New York, USA.
  • Center for Infectious Diseases and Immunology, Rochester General Hospital Research Institute, Rochester, New York, USA. Electronic address: Michael.pichichero@rochesterregional.org.

Förderung

  • NIAID NIH HHS
  • National Institutes of Health
  • National Institute on Deafness and Other Communication Disorders

Zitieren

APA

Kaur, R., Mangiafesto, J., Pryharski, K., Rasam, S., Zagursky, R., & Pichichero, M. (2023). Expression conditions and characterization of a novelly constructed lipoprotein intended as a vaccine to prevent human Haemophilus influenzae infections. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2023.105031

Vancouver

Kaur R, Mangiafesto J, Pryharski K, Rasam S, Zagursky R, Pichichero M. Expression conditions and characterization of a novelly constructed lipoprotein intended as a vaccine to prevent human Haemophilus influenzae infections. Journal of Biological Chemistry. 2023. doi:10.1016/j.jbc.2023.105031

BibTeX
@article{Kaur2023,
  author = {Kaur, Ravinder and Mangiafesto, Jill and Pryharski, Karin and Rasam, Sailee and Zagursky, Robert and Pichichero, Michael},
  title = {Expression conditions and characterization of a novelly constructed lipoprotein intended as a vaccine to prevent human Haemophilus influenzae infections},
  journal = {Journal of Biological Chemistry},
  year = {2023},
  doi = {10.1016/j.jbc.2023.105031}
}
Kostenlos starten →